Article
Rhythm Pharmaceuticals scores first FDA approval for obesity med targeting genetic defects
Rating:
0.0
Views:
91
Likes:
1
Library:
1
Obesity is a major problem worldwide, but, for a fraction of patients, genetic mutations rather than habits are driving the disease. With its new FDA approval for Imcivree, Rhythm Pharmaceuticals is taking the first step toward treating those cases.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value